Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.

BMC Nephrol · 2020 · PMC7160971 · PMID 32293308

Europe PMC DOI

hedged sentence

0.6780

closest p · 13.6× alpha

0.6780

boldest claim

The sentences

did not reach statistical significancep = 0.678not close (p > 0.1)

Although the overall remission rate of MCD patients was higher than those with FSGS, the difference did not reach statistical significance (80.3% for MCD and 53.6% for FSGS; Q-value = 1.661; p = 0.678).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.